Prescription Trends of Biologic DMARDs in Treating Rheumatologic Diseases: Changes of Medication Availability in COVID-19
Biologic disease-modifying antirheumatic drugs (DMARDs) are very effective in treating rheumatic diseases with a good patient tolerance. However, high cost and individualistic approach requires dedication of the physician. Therefore, the aim of this study was to determine how the COVID-19 pandemic h...
Gespeichert in:
| Veröffentlicht in: | Journal of personalized medicine 2023-07, Vol.13 (8), p.1199 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 8 |
| container_start_page | 1199 |
| container_title | Journal of personalized medicine |
| container_volume | 13 |
| creator | Radić, Mislav Đogaš, Hana Vrkić, Karla Gelemanović, Andrea Marinović, Ivanka Perković, Dijana Nazlić, Jurica Radić, Josipa Krstulović, Daniela Marasović Meštrović, Julije |
| description | Biologic disease-modifying antirheumatic drugs (DMARDs) are very effective in treating rheumatic diseases with a good patient tolerance. However, high cost and individualistic approach requires dedication of the physician. Therefore, the aim of this study was to determine how the COVID-19 pandemic has affected the prescription of biologic DMARDs in rheumatology at the University Hospital of Split. The data collection was conducted through an archive search in the Outpatient Clinic for Rheumatology in the University Hospital of Split, Split, Croatia. The search included the period before and after the start of the COVID-19 pandemic in Croatia (31 March 2020). Collected data included age, sex, ICD-10 code of diagnosis, generic and brand name of the prescribed drug, date of therapy initiation, and medication administration route. In the pre-COVID-19 period, 209 patients were processed, while in the COVID-19 period, 185 patients were processed (11.5% fewer). During pre-COVID-19, 231 biologic medications were prescribed, while during COVID-19, 204. During COVID-19, IL-6 inhibitors were less prescribed (48 (21%) vs. 21 (10%) prescriptions, p = 0.003), while IL-17A inhibitors were more prescribed (39 (17%) vs. 61 (30%) prescriptions, p = 0.001). In ankylosing spondylitis (AS), adalimumab was prescribed more during pre-COVID-19 (25 vs. 15 patients, p = 0.010), while ixekizumab was prescribed less (1 vs. 10 patients, p = 0.009). In rheumatoid arthritis, tocilizumab was prescribed more in the pre-COVID-19 period (34 vs. 10 patients, p = 0.012). Overall, the prescription trends of biologic DMARDs for rheumatologic diseases did not vary significantly in the University Hospital of Split, Croatia. Tocilizumab was prescribed less during COVID-19 due to shortages, while ixekizumab was more prescribed during COVID-19 due to an increase in psoriatic arthritis patients processed and due to being approved for treating AS. |
| doi_str_mv | 10.3390/jpm13081199 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10455961</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A762479631</galeid><sourcerecordid>A762479631</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-b762f9a42bc4cda5b2d2d201acff5656820684e2da4616fe9b323b673ad324503</originalsourceid><addsrcrecordid>eNptUltrFDEUDqLYUvvkHxjwRZCpuc-ML7Lueim0VEr1NWQyJ7NZZpI1mSnsvze7rbIVcx5yyPku-eAg9JrgC8Ya_H6zHQnDNSFN8wydUlyJknMqnx_1J-g8pQ3OpxaUSvwSnbBKUsYFPkW77xGSiW47ueCLuwi-S0WwxScXhtA7U6yuF7erVLjDUE_O98XtGuZRT38ALoFOkD4Uy7X2PRzo19A5ow-ai3vtBt26wU27vczy5uflqiTNK_TC6iHB-eN9hn58-Xy3_FZe3Xy9XC6uSsMJnco2f9U2mtPWcNNp0dIuFybaWCukkDXFsuZAO80lkRaallHWyorpjtEckZ2hjw-627kdoTPgp6gHtY1u1HGngnbq6cS7terDvSKYC9FIkhXePirE8GuGNKnRJQPDoD2EOSlai6rOVnWVoW_-gW7CHH3Od0DhWspjVK8HUM7bkI3NXlQtclxeNZLtbS_-g8rVwehM8GBdfn9CePdAMDGkFMH-DUmw2m-LOtoW9htBM67K</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2857086687</pqid></control><display><type>article</type><title>Prescription Trends of Biologic DMARDs in Treating Rheumatologic Diseases: Changes of Medication Availability in COVID-19</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><creator>Radić, Mislav ; Đogaš, Hana ; Vrkić, Karla ; Gelemanović, Andrea ; Marinović, Ivanka ; Perković, Dijana ; Nazlić, Jurica ; Radić, Josipa ; Krstulović, Daniela Marasović ; Meštrović, Julije</creator><creatorcontrib>Radić, Mislav ; Đogaš, Hana ; Vrkić, Karla ; Gelemanović, Andrea ; Marinović, Ivanka ; Perković, Dijana ; Nazlić, Jurica ; Radić, Josipa ; Krstulović, Daniela Marasović ; Meštrović, Julije</creatorcontrib><description>Biologic disease-modifying antirheumatic drugs (DMARDs) are very effective in treating rheumatic diseases with a good patient tolerance. However, high cost and individualistic approach requires dedication of the physician. Therefore, the aim of this study was to determine how the COVID-19 pandemic has affected the prescription of biologic DMARDs in rheumatology at the University Hospital of Split. The data collection was conducted through an archive search in the Outpatient Clinic for Rheumatology in the University Hospital of Split, Split, Croatia. The search included the period before and after the start of the COVID-19 pandemic in Croatia (31 March 2020). Collected data included age, sex, ICD-10 code of diagnosis, generic and brand name of the prescribed drug, date of therapy initiation, and medication administration route. In the pre-COVID-19 period, 209 patients were processed, while in the COVID-19 period, 185 patients were processed (11.5% fewer). During pre-COVID-19, 231 biologic medications were prescribed, while during COVID-19, 204. During COVID-19, IL-6 inhibitors were less prescribed (48 (21%) vs. 21 (10%) prescriptions, p = 0.003), while IL-17A inhibitors were more prescribed (39 (17%) vs. 61 (30%) prescriptions, p = 0.001). In ankylosing spondylitis (AS), adalimumab was prescribed more during pre-COVID-19 (25 vs. 15 patients, p = 0.010), while ixekizumab was prescribed less (1 vs. 10 patients, p = 0.009). In rheumatoid arthritis, tocilizumab was prescribed more in the pre-COVID-19 period (34 vs. 10 patients, p = 0.012). Overall, the prescription trends of biologic DMARDs for rheumatologic diseases did not vary significantly in the University Hospital of Split, Croatia. Tocilizumab was prescribed less during COVID-19 due to shortages, while ixekizumab was more prescribed during COVID-19 due to an increase in psoriatic arthritis patients processed and due to being approved for treating AS.</description><identifier>ISSN: 2075-4426</identifier><identifier>EISSN: 2075-4426</identifier><identifier>DOI: 10.3390/jpm13081199</identifier><identifier>PMID: 37623450</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Ankylosing spondylitis ; Antirheumatic agents ; Arthritis ; Autoimmune diseases ; B cells ; Biological products ; Brand names ; Care and treatment ; Clinics ; Coronaviruses ; COVID-19 ; Croatia ; Data collection ; Data entry ; Decision making ; Disease ; Drugs ; Epidemics ; Hospitals ; Interleukin 6 ; Monoclonal antibodies ; Outpatient care facilities ; Pandemics ; Patient satisfaction ; Patients ; Precision medicine ; Prescribing ; Prescription drugs ; Psoriatic arthritis ; Rheumatoid arthritis ; Rheumatoid factor ; Rheumatology ; Statistical analysis ; Statistical significance ; Trends ; Tumor necrosis factor-TNF</subject><ispartof>Journal of personalized medicine, 2023-07, Vol.13 (8), p.1199</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c412t-b762f9a42bc4cda5b2d2d201acff5656820684e2da4616fe9b323b673ad324503</cites><orcidid>0000-0002-2188-0006 ; 0000-0003-0350-6800 ; 0000-0001-9195-646X ; 0000-0003-2645-7597</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455961/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455961/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids></links><search><creatorcontrib>Radić, Mislav</creatorcontrib><creatorcontrib>Đogaš, Hana</creatorcontrib><creatorcontrib>Vrkić, Karla</creatorcontrib><creatorcontrib>Gelemanović, Andrea</creatorcontrib><creatorcontrib>Marinović, Ivanka</creatorcontrib><creatorcontrib>Perković, Dijana</creatorcontrib><creatorcontrib>Nazlić, Jurica</creatorcontrib><creatorcontrib>Radić, Josipa</creatorcontrib><creatorcontrib>Krstulović, Daniela Marasović</creatorcontrib><creatorcontrib>Meštrović, Julije</creatorcontrib><title>Prescription Trends of Biologic DMARDs in Treating Rheumatologic Diseases: Changes of Medication Availability in COVID-19</title><title>Journal of personalized medicine</title><description>Biologic disease-modifying antirheumatic drugs (DMARDs) are very effective in treating rheumatic diseases with a good patient tolerance. However, high cost and individualistic approach requires dedication of the physician. Therefore, the aim of this study was to determine how the COVID-19 pandemic has affected the prescription of biologic DMARDs in rheumatology at the University Hospital of Split. The data collection was conducted through an archive search in the Outpatient Clinic for Rheumatology in the University Hospital of Split, Split, Croatia. The search included the period before and after the start of the COVID-19 pandemic in Croatia (31 March 2020). Collected data included age, sex, ICD-10 code of diagnosis, generic and brand name of the prescribed drug, date of therapy initiation, and medication administration route. In the pre-COVID-19 period, 209 patients were processed, while in the COVID-19 period, 185 patients were processed (11.5% fewer). During pre-COVID-19, 231 biologic medications were prescribed, while during COVID-19, 204. During COVID-19, IL-6 inhibitors were less prescribed (48 (21%) vs. 21 (10%) prescriptions, p = 0.003), while IL-17A inhibitors were more prescribed (39 (17%) vs. 61 (30%) prescriptions, p = 0.001). In ankylosing spondylitis (AS), adalimumab was prescribed more during pre-COVID-19 (25 vs. 15 patients, p = 0.010), while ixekizumab was prescribed less (1 vs. 10 patients, p = 0.009). In rheumatoid arthritis, tocilizumab was prescribed more in the pre-COVID-19 period (34 vs. 10 patients, p = 0.012). Overall, the prescription trends of biologic DMARDs for rheumatologic diseases did not vary significantly in the University Hospital of Split, Croatia. Tocilizumab was prescribed less during COVID-19 due to shortages, while ixekizumab was more prescribed during COVID-19 due to an increase in psoriatic arthritis patients processed and due to being approved for treating AS.</description><subject>Ankylosing spondylitis</subject><subject>Antirheumatic agents</subject><subject>Arthritis</subject><subject>Autoimmune diseases</subject><subject>B cells</subject><subject>Biological products</subject><subject>Brand names</subject><subject>Care and treatment</subject><subject>Clinics</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Croatia</subject><subject>Data collection</subject><subject>Data entry</subject><subject>Decision making</subject><subject>Disease</subject><subject>Drugs</subject><subject>Epidemics</subject><subject>Hospitals</subject><subject>Interleukin 6</subject><subject>Monoclonal antibodies</subject><subject>Outpatient care facilities</subject><subject>Pandemics</subject><subject>Patient satisfaction</subject><subject>Patients</subject><subject>Precision medicine</subject><subject>Prescribing</subject><subject>Prescription drugs</subject><subject>Psoriatic arthritis</subject><subject>Rheumatoid arthritis</subject><subject>Rheumatoid factor</subject><subject>Rheumatology</subject><subject>Statistical analysis</subject><subject>Statistical significance</subject><subject>Trends</subject><subject>Tumor necrosis factor-TNF</subject><issn>2075-4426</issn><issn>2075-4426</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNptUltrFDEUDqLYUvvkHxjwRZCpuc-ML7Lueim0VEr1NWQyJ7NZZpI1mSnsvze7rbIVcx5yyPku-eAg9JrgC8Ya_H6zHQnDNSFN8wydUlyJknMqnx_1J-g8pQ3OpxaUSvwSnbBKUsYFPkW77xGSiW47ueCLuwi-S0WwxScXhtA7U6yuF7erVLjDUE_O98XtGuZRT38ALoFOkD4Uy7X2PRzo19A5ow-ai3vtBt26wU27vczy5uflqiTNK_TC6iHB-eN9hn58-Xy3_FZe3Xy9XC6uSsMJnco2f9U2mtPWcNNp0dIuFybaWCukkDXFsuZAO80lkRaallHWyorpjtEckZ2hjw-627kdoTPgp6gHtY1u1HGngnbq6cS7terDvSKYC9FIkhXePirE8GuGNKnRJQPDoD2EOSlai6rOVnWVoW_-gW7CHH3Od0DhWspjVK8HUM7bkI3NXlQtclxeNZLtbS_-g8rVwehM8GBdfn9CePdAMDGkFMH-DUmw2m-LOtoW9htBM67K</recordid><startdate>20230728</startdate><enddate>20230728</enddate><creator>Radić, Mislav</creator><creator>Đogaš, Hana</creator><creator>Vrkić, Karla</creator><creator>Gelemanović, Andrea</creator><creator>Marinović, Ivanka</creator><creator>Perković, Dijana</creator><creator>Nazlić, Jurica</creator><creator>Radić, Josipa</creator><creator>Krstulović, Daniela Marasović</creator><creator>Meštrović, Julije</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2188-0006</orcidid><orcidid>https://orcid.org/0000-0003-0350-6800</orcidid><orcidid>https://orcid.org/0000-0001-9195-646X</orcidid><orcidid>https://orcid.org/0000-0003-2645-7597</orcidid></search><sort><creationdate>20230728</creationdate><title>Prescription Trends of Biologic DMARDs in Treating Rheumatologic Diseases: Changes of Medication Availability in COVID-19</title><author>Radić, Mislav ; Đogaš, Hana ; Vrkić, Karla ; Gelemanović, Andrea ; Marinović, Ivanka ; Perković, Dijana ; Nazlić, Jurica ; Radić, Josipa ; Krstulović, Daniela Marasović ; Meštrović, Julije</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-b762f9a42bc4cda5b2d2d201acff5656820684e2da4616fe9b323b673ad324503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Ankylosing spondylitis</topic><topic>Antirheumatic agents</topic><topic>Arthritis</topic><topic>Autoimmune diseases</topic><topic>B cells</topic><topic>Biological products</topic><topic>Brand names</topic><topic>Care and treatment</topic><topic>Clinics</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Croatia</topic><topic>Data collection</topic><topic>Data entry</topic><topic>Decision making</topic><topic>Disease</topic><topic>Drugs</topic><topic>Epidemics</topic><topic>Hospitals</topic><topic>Interleukin 6</topic><topic>Monoclonal antibodies</topic><topic>Outpatient care facilities</topic><topic>Pandemics</topic><topic>Patient satisfaction</topic><topic>Patients</topic><topic>Precision medicine</topic><topic>Prescribing</topic><topic>Prescription drugs</topic><topic>Psoriatic arthritis</topic><topic>Rheumatoid arthritis</topic><topic>Rheumatoid factor</topic><topic>Rheumatology</topic><topic>Statistical analysis</topic><topic>Statistical significance</topic><topic>Trends</topic><topic>Tumor necrosis factor-TNF</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Radić, Mislav</creatorcontrib><creatorcontrib>Đogaš, Hana</creatorcontrib><creatorcontrib>Vrkić, Karla</creatorcontrib><creatorcontrib>Gelemanović, Andrea</creatorcontrib><creatorcontrib>Marinović, Ivanka</creatorcontrib><creatorcontrib>Perković, Dijana</creatorcontrib><creatorcontrib>Nazlić, Jurica</creatorcontrib><creatorcontrib>Radić, Josipa</creatorcontrib><creatorcontrib>Krstulović, Daniela Marasović</creatorcontrib><creatorcontrib>Meštrović, Julije</creatorcontrib><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of personalized medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Radić, Mislav</au><au>Đogaš, Hana</au><au>Vrkić, Karla</au><au>Gelemanović, Andrea</au><au>Marinović, Ivanka</au><au>Perković, Dijana</au><au>Nazlić, Jurica</au><au>Radić, Josipa</au><au>Krstulović, Daniela Marasović</au><au>Meštrović, Julije</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prescription Trends of Biologic DMARDs in Treating Rheumatologic Diseases: Changes of Medication Availability in COVID-19</atitle><jtitle>Journal of personalized medicine</jtitle><date>2023-07-28</date><risdate>2023</risdate><volume>13</volume><issue>8</issue><spage>1199</spage><pages>1199-</pages><issn>2075-4426</issn><eissn>2075-4426</eissn><abstract>Biologic disease-modifying antirheumatic drugs (DMARDs) are very effective in treating rheumatic diseases with a good patient tolerance. However, high cost and individualistic approach requires dedication of the physician. Therefore, the aim of this study was to determine how the COVID-19 pandemic has affected the prescription of biologic DMARDs in rheumatology at the University Hospital of Split. The data collection was conducted through an archive search in the Outpatient Clinic for Rheumatology in the University Hospital of Split, Split, Croatia. The search included the period before and after the start of the COVID-19 pandemic in Croatia (31 March 2020). Collected data included age, sex, ICD-10 code of diagnosis, generic and brand name of the prescribed drug, date of therapy initiation, and medication administration route. In the pre-COVID-19 period, 209 patients were processed, while in the COVID-19 period, 185 patients were processed (11.5% fewer). During pre-COVID-19, 231 biologic medications were prescribed, while during COVID-19, 204. During COVID-19, IL-6 inhibitors were less prescribed (48 (21%) vs. 21 (10%) prescriptions, p = 0.003), while IL-17A inhibitors were more prescribed (39 (17%) vs. 61 (30%) prescriptions, p = 0.001). In ankylosing spondylitis (AS), adalimumab was prescribed more during pre-COVID-19 (25 vs. 15 patients, p = 0.010), while ixekizumab was prescribed less (1 vs. 10 patients, p = 0.009). In rheumatoid arthritis, tocilizumab was prescribed more in the pre-COVID-19 period (34 vs. 10 patients, p = 0.012). Overall, the prescription trends of biologic DMARDs for rheumatologic diseases did not vary significantly in the University Hospital of Split, Croatia. Tocilizumab was prescribed less during COVID-19 due to shortages, while ixekizumab was more prescribed during COVID-19 due to an increase in psoriatic arthritis patients processed and due to being approved for treating AS.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>37623450</pmid><doi>10.3390/jpm13081199</doi><orcidid>https://orcid.org/0000-0002-2188-0006</orcidid><orcidid>https://orcid.org/0000-0003-0350-6800</orcidid><orcidid>https://orcid.org/0000-0001-9195-646X</orcidid><orcidid>https://orcid.org/0000-0003-2645-7597</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2075-4426 |
| ispartof | Journal of personalized medicine, 2023-07, Vol.13 (8), p.1199 |
| issn | 2075-4426 2075-4426 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10455961 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central |
| subjects | Ankylosing spondylitis Antirheumatic agents Arthritis Autoimmune diseases B cells Biological products Brand names Care and treatment Clinics Coronaviruses COVID-19 Croatia Data collection Data entry Decision making Disease Drugs Epidemics Hospitals Interleukin 6 Monoclonal antibodies Outpatient care facilities Pandemics Patient satisfaction Patients Precision medicine Prescribing Prescription drugs Psoriatic arthritis Rheumatoid arthritis Rheumatoid factor Rheumatology Statistical analysis Statistical significance Trends Tumor necrosis factor-TNF |
| title | Prescription Trends of Biologic DMARDs in Treating Rheumatologic Diseases: Changes of Medication Availability in COVID-19 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T11%3A49%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prescription%20Trends%20of%20Biologic%20DMARDs%20in%20Treating%20Rheumatologic%20Diseases:%20Changes%20of%20Medication%20Availability%20in%20COVID-19&rft.jtitle=Journal%20of%20personalized%20medicine&rft.au=Radi%C4%87,%20Mislav&rft.date=2023-07-28&rft.volume=13&rft.issue=8&rft.spage=1199&rft.pages=1199-&rft.issn=2075-4426&rft.eissn=2075-4426&rft_id=info:doi/10.3390/jpm13081199&rft_dat=%3Cgale_pubme%3EA762479631%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2857086687&rft_id=info:pmid/37623450&rft_galeid=A762479631&rfr_iscdi=true |